Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 15,972	$ 3,193
Property, plant and improvements
Property and equipment, net	157,317	166,509
Other assets
Operating lease right-of-use assets	250,484
Other receivable	419,958	418,905
Note receivable – related party	44,859	44,859
Advances to CEN Biotech Ukraine LLC – related party	995,328	875,328
Intangible assets, net	5,593,365	5,805,771
Total assets	7,477,283	7,314,565
Current liabilities
Accounts payable	206,521	206,521
Loans payable	10,119,178	10,107,205
Loans payable – related parties	1,362,318	1,360,806
Convertible notes payable	4,318,916	3,597,760
Convertible notes payable – related parties	926,368	926,368
Accrued interest	8,206,898	6,860,494
Accrued interest – related parties	1,119,126	946,227
Operating lease liabilities	42,306
Accrued expenses	492,235	402,377
Total current liabilities	26,793,866	24,407,758
Operating lease liabilities, less current portion	205,327
Patent acquisition liability	1,010,000	1,010,000
Convertible notes, less current portion	1,386,122	1,545,887
Convertible notes – related parties, less current portion	1,632,313	1,612,313
Total liabilities	31,027,628	28,575,958
Shareholders’ deficit
Common stock; unlimited authorized shares; 26,813,363 and 25,473,363 issued and outstanding as of June 30, 2019 and December 31, 2018, respectively. No par value.
Additional paid-in capital	15,198,110	14,393,660
Accumulated deficit	(38,748,455)	(35,655,053)
Total shareholders’ deficit	(23,550,345)	(21,261,393)
Total liabilities and shareholders’ deficit	$ 7,477,283	$ 7,314,565